Evidence map›Paper›PMID 40916005›Full record

ArticleEpidemiology and infection2025

Estimating the national seroprevalence of

Sara Mazzilli, Mathieu Tourdjman, Harold Noël, Anna Maisa, Isabelle Villena, Camille Le-Ray, ENP2021 study group

Abstract read
In one paragraph

Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sara MazzilliDepartment of Infectious Diseases, French National Public Health Agency (Santé publique France), Saint-Maurice, France.ORCID https://orcid.org/0000-0002-7989-0661
Mathieu TourdjmanDepartment of Infectious Diseases, French National Public Health Agency (Santé publique France), Saint-Maurice, France.ORCID https://orcid.org/0000-0001-8368-8485
Harold NoëlDepartment of Infectious Diseases, French National Public Health Agency (Santé publique France), Saint-Maurice, France.ORCID https://orcid.org/0000-0003-3011-9267
Anna MaisaDepartment of Infectious Diseases, French National Public Health Agency (Santé publique France), Saint-Maurice, France.
Isabelle VillenaNational Reference Centre for Toxoplasmosis, Hospital, University Reims Champagne-Ardenne, Reims, France.
Camille Le-RayCentre of Research In Epidemiology and Statistics (CRESS), Obstetric, Perinatal, Paediatric Life Course Epidemiology (OPPaLE) Research Team, Université Paris Cité, Institut Santé des femmes, U1153, INSERM, INRAE, Paris, France.
ENP2021 study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxoplasmosis during pregnancy can cause congenital malformations and fetal death. This study aimed to estimate the

Indexed as

Pregnancy Complications, ParasiticToxoplasmaToxoplasmosisAdolescentAdultAntibodies, ProtozoanFemaleFranceHumansPregnancyPrevalenceRisk FactorsSeroepidemiologic StudiesYoung AdultAntibodies, ProtozoanFrancepregnant womanseroconversionseroprevalenceToxoplasma gondiitoxoplasmosis

Identifiers

PMID40916005
PMCPMC12455506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.